A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat (LBH589) When Administered In Combination With Lenalidomide And Weekly Dexamethasone In Patients With Multiple Myeloma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- The Best Overall Response Rate (ORR)
研究概览
简要总结
The purpose of this clinical research study is to find out the effects of a drug called panobinostat (LBH589) when given to people like you with multiple myeloma in combination with the drugs lenalidomide and dexamethasone. The safety of this combination of drugs will also be studied. Your physical state, changes in the state of your multiple myeloma, and laboratory findings taken while on-study will help us decide if panobinostat combined with dexamethasone and lenalidomide is safe and effective.
This goal of this study therefore is to determine the activity of the combination of panobinostat thrice weekly every other week, lenalidomide, and weekly dexamethasone in a similar group of subjects. The doses of lenalidomide and dexamethasone will be that which is approved by the FDA for multiple myeloma and you will take each drug at a specific frequency over a 4 week (28 day) period. This period is called a "study cycle".
详细描述
The study drug, panobinostat, is made by Novartis Pharmaceuticals Corporation. Panobinostat has not yet been approved by the Food and Drug Administration (FDA) and thus is considered an experimental drug in this research study. Panobinostat is not available to you "on the market" (available for you to buy). It is only available in clinical trials for patients like you with your medical condition. Panobinostat is a drug that may slow down the growth of multiple myeloma or kill multiple myeloma cells by blocking certain enzymes (proteins produced by cells). Panobinostat has shown effects against cancers such as multiple myeloma in laboratory studies and in studies using animals; however, it is not known if this medicine will show the same activity in humans. As of 31st December 2009, a total of 1116 patients have already received treatment with panobinostat.
Unlike panobinostat, lenalidomide (Revlimid©) and dexamethasone are approved by the FDA and are already available for purchase on the US market. Clinical trials have shown that lenalidomide, especially taken with dexamethasone, produces positive clinical responses with manageable side effects when given to subjects with multiple myeloma.
In this study, subjects will take panobinostat capsules, lenalidomide, and dexamethasone all orally. The purpose of this combination is to interfere with the cancerous cells in multiple and different ways as each of these drugs acts differently on cancer cells. By combining the drugs and giving them at the same time, it might be possible to slow the progression of your disease, rather than if study drugs were given separately. Researchers have combined laboratory studies on animals with this drug combination and the combined effect has been shown to be worthwhile to justify clinical trials in humans.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a history of symptomatic multiple myeloma according to the International Myeloma Working Group criteria (IMWG, 2003), as defined as the following three criteria:
- •Clonal plasma cells >10% on bone marrow biopsy
- •A monoclonal protein (paraprotein) in either serum or urine(except in cases of non-secretory myeloma)
- •Evidence of end-organ damage felt related to the plasma cell disorder (related organ or tissue impairment, ROTI, commonly referred to by the acronym "CRAB"):
- •Hypercalcemia serum Ca ≥ 11.5 mg/dL or
- •Renal insufficiency attributable to myeloma. Serum creatinine > 2mg/dL
- •Anemia: Normochromic, normocytic with a hemoglobin value > 2g/dL below the lower limit of normal or a hemoglobin <10 g/dL
- •Bone lesions (lytic lesions, severe osteopenia or pathologic fractures
- •Patients must have received at least one prior line of therapy. For example; One prior line of therapy may consist of all predetermined components of induction followed by autologous stem cell transplantation and maintenance.
- •Patient has relapsed or relapsed/refractory MM.
- •Relapsed is defined as the development of disease progression following the achievement of stable disease (SD) or better to the most recent anti-MM regimen.
- •Refractory is defined as experiencing less than a partial response (PR) to or progressive disease (PD) within 6 months after completion of the most recent anti-MM regimen.
- •Patients must currently have measureable disease, as defined as:
- •a. Serum M protein ≥ 1.0 g/dl (≥ 10 mg/l)
- •Urine M protein ≥ 200 mg/24h
- •Serum free light chain assay: involved FLC level ≥ 10mg/dl (≥ 100 mg/l) provided serum FLC ratio is abnormal
- •If no monoclonal protein is detected (non-secretory disease), then > 30% monoclonal bone marrow plasma cells.
- •Patients must be suitable (according to their local product information) for treatment or re-treatment with lenalidomide & dexamethasone. Note: patients previously treated with lenalidomide & dexamethasone are eligible to participate in the trial.
- •Male or female adults ≥ 18 years old
- •ECOG Performance Status ≤ 2
- •Life expectancy > 12 weeks
- •Patients must have the following laboratory values:
- •ANC ≥ 1.5 x 109/L for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or an ANC > 1.0 x 109/Lfor patients in whom > 50% of bone marrow nucleated cells are plasma cells.
- •Hemoglobin ≥ 9 g/dl
- •Platelets ≥ 75x 109/L for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or > 50 x 109/L for patients in whom > 50% of bone marrow nucleated cells are plasma cells.
- •Calculated CrCl ≥ 50 mL/min (MDRD Formula)
- •AST and ALT ≤ 2.5 x ULN,
- •Serum bilirubin ≤ 1.5 x ULN
- •Electrolytes:
- •Serum potassium ≥ LLN,
- •Total serum calcium [corrected for serum albumin] or ionized calcium ≥LLN
- •Serum magnesium ≥ LLN
- •Serum phosphorus ≥ LLN
- •Normal thyroid function (TSH and free T4) (Clinically euthyroid patients are acceptable).
- •Able to sign informed consent and to comply with the protocol
- •Exclusion criteria
- •Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatment
- •Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:
- •History or presence of sustained ventricular tachyarrhythmia. (Patients with a history of atrial arrhythmia are eligible but should be discussed with Novartis prior to enrollment)
- •Any history of ventricular fibrillation or torsade de pointes
- •Bradycardia defined as HR< 50 bpm. Patients with pacemakers are eligible if resting HR ≥ 50 bpm.
- •Screening ECG with a QTc > 450 msec
- •Right bundle branch block + left anterior hemiblock (bifascicular block)
- •Patients with myocardial infarction or unstable angina ≤ 6 months prior to starting study drug
- •Other clinically significant heart disease (e.g., CHF NY Heart Association class III or IV , uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
- •Impairment of GI function or GI disease that may significantly alter the absorption of panobinostat
- •Patients with diarrhea > CTCAE grade 2
- •Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes or active or uncontrolled infection) including abnormal laboratory values, that could cause unacceptable safety risks or compromise compliance with the protocol
- •Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug
- •Patients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies.
- 另有 13 项未显示
排除标准
- 未提供
研究组 & 干预措施
Panobinostat, Lenalidomide and Dexamethasone
All patients will receive oral panobinostat, lenalidomide and dexamethasone as per protocol.
干预措施: Panobinostat (Drug)
Panobinostat, Lenalidomide and Dexamethasone
All patients will receive oral panobinostat, lenalidomide and dexamethasone as per protocol.
干预措施: Dexamethasone (Drug)
Panobinostat, Lenalidomide and Dexamethasone
All patients will receive oral panobinostat, lenalidomide and dexamethasone as per protocol.
干预措施: Lenalidomide (Drug)
结局指标
主要结局
The Best Overall Response Rate (ORR)
时间窗: up to 4 years
The primary endpoint will be the best overall response rate (ORR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Overall Response Rate for Len Refractory Patients
时间窗: up to 4 years
The primary endpoint will be the best overall response rate (ORR)
次要结局
- Disease Control Rate for Lens Refractory Rate(up to 4 years)
- Response Rates(up to 4 years)
- Response Rates for Len Refractory Patients(up to 4 years)
- Clinical Benefit Rate(up to 4 years)
- Clinical Benefit Rate for Len Refractory Patients(up to 4 years)
- Disease Control Rate(up to 4 years)
研究者
Ajai Chari
Associate Professor
Icahn School of Medicine at Mount Sinai